<DOC>
	<DOC>NCT01513460</DOC>
	<brief_summary>This study will assess the efficacy, tolerability and safety of NVA237 compared to tiotropium when added on to fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.</brief_summary>
	<brief_title>Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Patients with Moderate to Severe COPD (Stage II or Stage III) according to the GOLD 2010 guideline Current or exsmokers who have a smoking history of at least 10 pack years Qualifying FEV1 at Visit 2 (day 7) Patients with a history of asthma or a history of high blood eosinophil count (&gt;600/mm³) Patients with concomitant pulmonary disease Patients with lung lobectomy or lung volume reduction or lung transplantation Patients with α1 antitrypsin deficiency Patients who have had live attenuated vaccinations within 30 days prior to screening visit or during runin period Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease,</keyword>
	<keyword>NVA 237,</keyword>
	<keyword>glycopyrronium,</keyword>
	<keyword>COPD</keyword>
</DOC>